You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股收評:3600點再失守,AI軟硬件攜手上升,創新藥、軍工表現活躍

今日,A股三大指數集體下挫,滬指跌1.18%報3573點,深證成指跌1.73%,創業板指跌1.66%。

全天成交1.96萬億元,較前一交易日增量909億元,全市場近4300股下跌。

盤面上,鋼鐵板塊走低,包鋼股份跌近8%。煤炭股普跌,安泰集團跌近7%。

水產養殖板塊走弱,中水漁業領跌。鋰礦概念震盪下行,盛鑫鋰能、寧德時代等多股跌近5%。

鈦白粉、光伏設備、船舶製造、小金屬及免税概念等跌幅居前。

另外,液冷概念逆市走高,劍橋科技、淳中科技及冰輪環境等多股升停。

31省將輔助生殖技術納入醫保,輔助生殖板塊拉昇,安科生物、漢商集團等多股升停。

複合集流體板塊活躍,諾德股份升停;基因測序、智譜AI及國資雲概念等升幅居前。

具體來看:

液冷等AI硬件板塊大升居前,思泉新材20CM升停,方盛股份升超15%,科創新源升超12%,鼎通科技升超10%,大元泵業、英維克、淳中科技、冰輪環境、川潤股份升停,川環科技升超8%,申菱環境、神州數碼升超7%,依米康升超6%。

AI軟件板塊同步走強,易點天下20CM升停,亞信安全、永信至誠、值得買升超7%,新致軟件、三六零升超6%,視覺中國、藍色光標升超4%,因賽集團、豆神教育升超3%。

輔助生殖板塊繼續大升,安科生物、共同藥業、利德曼20CM升停,貝瑞基因升超4%,貝因美升超3%。

創新藥表現活躍,南新制藥、安科生物20CM升停,廣生堂升超18%,振東製藥升超16%,舒泰神升超10%,昂利康、貴州百靈、德展健康升停,星昊醫藥、海特生物升超8%,翰宇藥業、百誠醫藥升超7%。

軍工板塊回暖,西菱動力20CM升停,北方長龍升超17%,航天晨光、長城軍工升停,西寧特鋼等升超6%,捷強裝備等升超5%。

鋼鐵板塊領跌,包鋼股份、安陽鋼鐵、盛德鑫泰跌超7%,重慶鋼鐵、本鋼板材、馬鋼股份、首鋼股份跌超5%,八一鋼鐵、鞍鋼股份等跌超4%。

煤炭板塊走低,潞安環能、平煤股份、鄭州煤電、晉控煤業、山西焦煤跌超4%,雲煤能源、陝西黑貓等跌超3%。

地產股大跌,城建發展、招商蛇口、張江高科、金地集團跌超5%,招商積餘、光大嘉寶、綠地控股、濱江集團、保利發展等跌超4%。

化工股走低,魯西化工跌超6%,湖北宜化、興發集團跌超4%,清水源、六國化工跌超3%,四川美豐跌超2%。

展望未來,中信證券認為,當前依然是平衡港A配比的好時機,建議增配恒生科技。其次,建議關注科創50、科創芯片、科創100的補升機會。最後,當前至中報季結束,依然建議A股圍繞有色、通信、創新藥、軍工、遊戲五個行業輪動,同時以主題思維切入一些反內卷品種;中報季末尾,如果伴隨着關税戰預期的穩定,出海可能會重新形成板塊性行情接力。這些前期升幅相對較小的板塊,有望受益於人工智能大會的事件催化及科創板開市6週年的政策催化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account